On Friday, the Trump administration announced finalized Medicare and Medicaid policies, causing Eli Lilly stock to drop. The exclusion of weight-loss drugs led to a dive in Eli Lilly and Novo stocks. The decision had significant effects on the market, with Eli Lilly experiencing a noticeable decline in stock value.